Key value drivers
Therapeutics: AfaSci has developed three very interesting drug candidate series:
- Small orally available molecules for central nervous system analgesia with anti-inflammatory effects
- Small orally available molecules for central nervous system anti-seizures with anti-inflammatory effects
Technology: AfaSci's SmartCagetm system performs up to 20 automated behavioral assays, resulting in increased throughput in vivo drug screening and objective and chronic behaviroal testing, while reducing costs for in vivo behavioral phenotyping, drug screening, and pharmacology.
Our competitive advantages include:
- Novel drug candidates in clinical development and some pipeline compounds are ready for IND-enabling studies
- Proprietary technologies
- In-house research capacity in electrophysiology and in vivo pharmacology.
AfaSci has built a highly productive research team with complementary skill sets, and enjoys broad academic collaborations.